Literature DB >> 7290153

Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes.

J Newsom-Davis, N Willcox, L Calder.   

Abstract

We investigated the role of the thymus in 16 patients with myasthenia gravis without thymoma by studying the production of anti-acetylcholine-receptor antibody by thymic and blood lymphocytes cultured alone or together. In 19 responders (with the highest receptor-antibody titers in their plasma), cultured thymic cells spontaneously produced measurable receptor antibody. Receptor-antibody production by autologous blood lymphocytes was enhanced by the addition of responders' thymic cells, irradiated to abrogate antibody production and suppression (P less than 0.01). This enhancement was greater and more consistent than that by pokeweed mitogen; it depended on viable thymic cells, appeared to be selective for receptor antibody, and correlated with the ratio of thymic helper (OKT4-positive or OKT4+) to suppressor (OKT8+) T cells (P less than 0.01). These results suggest that myasthenic thymus contains cell-bound acetylcholine-receptor-like material or specific T cells (or both) that can aid receptor-antibody production. This may be relevant to the benefits of thymectomy in myasthenia and to the breakdown in self-tolerance in this and other autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7290153     DOI: 10.1056/NEJM198111263052203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  23 in total

Review 1.  Intrathymic expression of neuromuscular acetylcholine receptors and the immunpathogenesis of myasthenia gravis.

Authors:  Arnold I Levinson; Yi Zheng; Glen Gaulton; Decheng Song; Jonni Moore; C Hank Pletcher
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.

Authors:  F Heidenreich; T Jovin
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

3.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

Review 4.  Immunopathogenesis and treatment of myasthenia gravis.

Authors:  A I Levinson; B Zweiman; R P Lisak
Journal:  J Clin Immunol       Date:  1987-05       Impact factor: 8.317

5.  Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients.

Authors:  A Melms; B C Schalke; T Kirchner; H K Müller-Hermelink; E Albert; H Wekerle
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

6.  Phenotypic characteristics of thymic B lymphocytes in myasthenia gravis.

Authors:  B Zweiman; A I Levinson; R P Lisak
Journal:  J Clin Immunol       Date:  1989-05       Impact factor: 8.317

7.  Microenvironments in the normal thymus and the thymus in myasthenia gravis.

Authors:  M Bofill; G Janossy; N Willcox; M Chilosi; L K Trejdosiewicz; J Newsom-Davis
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

Review 8.  Phenotypic and functional analysis of lymphocytes in myasthenia gravis.

Authors:  A I Levinson; R P Lisak; B Zweiman; M Kornstein
Journal:  Springer Semin Immunopathol       Date:  1985

9.  Myasthenia gravis: overlap with 'polyendocrine' autoimmunity.

Authors:  W A Scherbaum; F Schumm; B Maisch; C Müller; A Fateh-Moghadam; S H Flüchter; F J Seif; G F Bottazzo; P A Berg
Journal:  Klin Wochenschr       Date:  1983-05-16

10.  The relation of clinical disease to antibody titre, proliferative response and neurophysiology in murine experimental autoimmune myasthenia gravis.

Authors:  A R Pachner; F S Kantor
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.